c-Myc antibody [33]

GeneTex

c-Myc antibody [33]

9

IF: Use at an assay dependent dilution. IHC-Fr: Use at an assay dependent dilution. Myc is a labile protein, thereforepreotease inhibitors should be used at all times. IP (with and without SDS): Use at an assay dependent dilution. WB: Use at an assay dependent dilution. Detects a band of approximately 49, 64 & 67 kD (predicted molecular weight: 49 kD). 64 and 67kD forms are phosphophorylated. Optimal dilutions/concentrations should be determined by the end user.

ImmunoFluorescence, ImmunoPrecipitation, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Frozen

Research Use Only

Monoclonal

33

1 mg/ml

Unconjugated

MYC

MYC proto-oncogene, bHLH transcription factor

avian myelocytomatosis viral oncogene homolog; bHLHe39; class E basic helix-loop-helix protein 39; c-Myc; MRTL; myc proto-oncogene protein; MYCC; myc-related translation/localization regulatory factor; proto-oncogene c-Myc; transcription factor p64; v-myc avian myelocytomatosis viral oncogene homolog; v-myc myelocytomatosis viral oncogene homolog

Mouse

IgG1

Myc proto-oncogene protein

This gene is a proto-oncogene and encodes a nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. The encoded protein forms a heterodimer with the related transcription factor MAX. This complex binds to the E box DNA consensus sequence and regulates the transcription of specific target genes. Amplification of this gene is frequently observed in numerous human cancers. Translocations involving this gene are associated with Burkitt lymphoma and multiple myeloma in human patients. There is evidence to show that translation initiates both from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site, resulting in the production of two isoforms with distinct N-termini. [provided by RefSeq, Aug 2017]

Avian, Human, Mouse, Rat

-20°C or -80°C,2°C to 8°C

12352203